In response to: “Reply to research letter”

Gelijkaardige items

• Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”
  door: Wan, Marilyn T., et al.
  Gepubliceerd in: (2020)
• Reply to research letter
  door: Rivera-Oyola, Ryan, et al.
  Gepubliceerd in: (2020)
• The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  door: Wan, Marilyn T., et al.
  Gepubliceerd in: (2020)
• The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
  door: Syed, Maha N., et al.
  Gepubliceerd in: (2020)
• Commentary
  door: Shin, Daniel B., et al.
  Gepubliceerd in: (2021)